Evidence mapPaperPMID 41348183Full record

ReviewCell biochemistry and biophysics2026

Ferritinophagy as a Double-Edged Sword in Cancer: Novel Insights into Therapeutic Targeting of Iron-Driven Ferroptosis.

Omar I Badr, Fayrouz A Mustafa, Basant A Radwan, Ammar M Abdulfatah, Ahmed N Ragab, Hameis M Sleem

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Omar I BadrDepartment Of Pharmacology and Biochemistry, Faculty of Pharmacy, The British University in Egypt, El Sherouk City, Egypt.
Fayrouz A MustafaFinal Year Pharmacy students, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt.
Basant A RadwanFinal Year Pharmacy students, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt.
Ammar M AbdulfatahFinal Year Pharmacy students, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt.
Ahmed N RagabFinal Year Pharmacy students, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt.
Hameis M SleemDepartment Of Pharmacology and Biochemistry, Faculty of Pharmacy, The British University in Egypt, El Sherouk City, Egypt. Hameis.sleem@bue.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron metabolism and its regulation through ferritinophagy have emerged as critical yet under-explored determinants of cancer cell fate, uniquely bridging essential biological processes such as DNA synthesis, oxidative metabolism and cellular respiration with iron-dependent cell death pathways like ferroptosis. This review presents a novel and integrative analysis of ferritinophagy mediated predominantly by nuclear receptor coactivator 4 (NCOA4) as a pivotal regulator of iron homeostasis, exhibiting highly context-dependent roles in cancer progression, survival and therapeutic resistance. We synthesize recent mechanistic advances to show how ferritinophagy can either support tumor growth by satisfying iron-driven metabolic demands or trigger ferroptosis-mediated tumor suppression; a duality seldom examined in prior literature. We further examine the interplay between ferritinophagy and antioxidant defense systems, particularly the NRF2 signaling network, and how this balance affects treatment outcomes. Importantly, we consolidate emerging therapeutic strategies that exploit ferritinophagy modulation namely targeted small molecules, bioactive natural compounds, nanotechnology-facilitated delivery systems, and RNA-based interventions thereby positioning ferritinophagy as a promising target in precision oncology. We then critically discuss the major translational challenges: tumor heterogeneity in iron-metabolism phenotypes, the risk of off-target toxicity disrupting systemic iron homeostasis, the dearth of reliable biomarkers to monitor ferritinophagy flux and delivery/pharmacokinetic limitations in reaching specific tumor niches. Our integrative approach offers fresh perspectives on how ferritinophagy interfaces with cancer-relevant pathways across diverse tumor types, emphasizing its potential both as a vulnerability to exploit and a mechanism of resistance to overcome. This work thus lays a foundation for future research into ferritinophagy-centred interventions that may enhance cancer treatment efficacy.

Indexed as

AutophagyFerritinsFerroptosisIronNeoplasmsAnimalsHumansNF-E2-Related Factor 2Nuclear Receptor CoactivatorsSignal TransductionFerritinsIronNCOA4 protein, humanNF-E2-Related Factor 2Nuclear Receptor CoactivatorsCancerFerritinophagyFerroptosisNCOA4

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.